Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-06-26
1997-10-07
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514453, 514455, 514511, A61K 3135
Patent
active
056748930
ABSTRACT:
A method is provided for preventing or reducing the risk of onset of a cardiovascular event by administering an HMG CoA reductase inhibitor such as pravastatin, to a patient which has one or more risk factors for a coronary and/or cerebrovascular event such as hypercholesterolemia.
REFERENCES:
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4920123 (1990-04-01), Beyer
patent: 5008284 (1991-04-01), Grover et al.
Cecil, Textbook of Medicine, 16 Ed., pp. 239-241. (1980).
Schettler, G., "The role of diet and drugs in lowering serum cholesterol in the postmyocardial infarction patient," Cardiovasc. Drugs, Ther., 1989, 2/6 (795-799).
Glatter, T.R., "Hyperlipidemia. What is `normal`, who should treated and how," Postgrad. Med., 1984, 76/6 (49-50).
Satler, L.F., et al, "Reduction in coronary heart disease: Clinical and anatomical considerations," Clin. Cardiol., 1989, 12/8 (422-426).
Wilhelmsen, L., "Practical Guidelines for drug therapy after myocardial infarction," Drugs, 1989, 38/6 (1999-1007).
Yamamoto, A., et al, "Clinical features of familial hypercholesterolemia," Arteriosclerosis, Jan.-Feb. 1989, 9 (1 Suppl.) pp. I66-74.
Goldstein, J.L., et al, "The LDL receptor defect in familial hypercholesterolemia. Implications for pathogenesis and therapy," Med. Clin. North Am., 1982, 66/2 (335-362).
Osborne, J.A., et al, "Anti-ischemic Actions of Lovastatin (1) in Hypercholesterolemic Rabbits," Abstract of the 61st Scientific Sessions.
Tsujita, Y. "A Potent HMG-CoA Reductase Inhibitor, Pravastat Sodium-Tissue-Selective Inhibition of Cholesterolgenesis and Preventive Effect on Atherosclerosis in WHHL Rabbits," J. Drug Dev. 1990:3 (Suppl. 1), 155-159.
Maher, V.M., et al, "Analysis of Evidence from Cholesterol-Lowering and Regression Trials," J. Drug Dev. 1990:3 (Suppl. 1 ) 199-203.
Lewis, B. "On lowering lipids in the post-infarction patient", Journal of Internal Medicine 1991; 29:483-488.
"A Cornary Primary Prevention Study of Scottish Men Aged 45-64 Years: Trial Design," J. Clin. Epidemiol vol. 45, No. 8 pp. 849-860, 1992.
Goldman, L., et al, "Projected Cost-Effectiveness of Lovastatin for Cholesterol Reduction," Clin. Res. (36, No. 3, 337A, 1988).
Sacks, F.M. et al, "Rationale and design of a Secondary Prevention Trial of Lowering Normal Plasma Cholesterol Levels After Acute Myocardial . . . Recurrent Events Trial (CARE)", Am. J. Card. vol. 68, Dec. 1, 1991, pp. 1436-1446.
Fuster, V., et al, "Atherosclerotic Plaque Rupture and Thrombosis," Suppl. II, Circulation, vol. 82, No. 3, Sep. 1990, II-47-II59.
Crouse, J.R., et al, "Pravastatin, Lipids, and Arterosclerosis in the Carotid Arteries: Design Features of a Clinical Trial with Carotid Atheries: Design Features of a Clinical Trial with Carotid Artherosclerosis Outcome," Controlled Clinical Trials 13:495-506 (1992).
Edelman, S., et al, "Hyperkalemia During Treatment with HMG-CoA Reductase Inhibitor," New Engl. J. of Med., vol. 320, No. 18, May 4, 1989, pp. 1219-1220.
Pitt, B., et al, "Design and Recruitment in the United States of a Multicenter Quantitative Angiographic Trial of Pravastat to Limit Atherosclerosis in the Coronary Arteries (PLAC I)", Amer. J. Card., vol. 72, Jul. 1, 1993, pp. 31-35.
"Effects of Pravastatin in Patients with Serum Total Cholesterol Levels from 5.2 to 7.8 mmol/liter (200 to 30 mg/dl) Plu Two Additional Atherosclerotic Risk Factors," Am. J. Card., Nov. 1, 1993, pp. 1031-1037.
Pearson, T.A., et al, "The Rapid Reduction in Cardiac Events with Lipid-Lowering Therapy: Mechanisms and Implications," Am. J. Card., vol. 72, Nov. 1, 1993, pp. 1072-1073.
Behounek Bruce D.
McGovern Mark E.
Olukotun Adeoye Y.
Bristol--Myers Squibb Company
Criares Theodore J.
Rodney Burton
LandOfFree
Method for preventing reducing or risk of onset of cerebrovascul does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preventing reducing or risk of onset of cerebrovascul, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preventing reducing or risk of onset of cerebrovascul will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2357711